Akari Therapeutics Plc Files Definitive Proxy Statement
Ticker: AKTX · Form: DEF 14A · Filed: Jun 3, 2024 · CIK: 1541157
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Akari Therapeutics DEF 14A is out - proxy materials for shareholder votes on directors & auditors.
AI Summary
Akari Therapeutics Plc filed a definitive proxy statement (DEF 14A) on June 3, 2024, for its annual general meeting. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders, including the re-election of directors and the appointment of auditors.
Why It Matters
This filing provides shareholders with crucial information regarding company management and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently present new financial or operational risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc. (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon, such as director elections and auditor appointments.
When was this DEF 14A filed by Akari Therapeutics Plc?
Akari Therapeutics Plc filed this DEF 14A on June 3, 2024.
What are some key items typically found in a DEF 14A filing?
Key items typically include information on director nominations, executive compensation, corporate governance, and proposals submitted for shareholder vote.
What is the standard industrial classification for Akari Therapeutics Plc?
The standard industrial classification for Akari Therapeutics Plc is Pharmaceutical Preparations [2834].
Has Akari Therapeutics Plc had previous company names?
Yes, Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc. (name change date: 20130621) and Morria Biopharmaceuticals PLC (name change date: 20120201).
Filing Stats: 4,897 words · 20 min read · ~16 pages · Grade level 11.7 · Accepted 2024-06-03 16:21:04
Filing Documents
- tm2416228d1_def14a.htm (DEF 14A) — 709KB
- image_003.jpg (GRAPHIC) — 28KB
- image_004.jpg (GRAPHIC) — 27KB
- tm2416228d1_def14aimg003.jpg (GRAPHIC) — 8KB
- tm2416228d1_def14aimg004.jpg (GRAPHIC) — 8KB
- tm2416228d1_def14aimg005.jpg (GRAPHIC) — 96KB
- tm2416228d1_def14img001.jpg (GRAPHIC) — 177KB
- tm2416228d1_def14img002.jpg (GRAPHIC) — 185KB
- 0001104659-24-067797.txt ( ) — 1439KB
SECURITY OWNERSHIP OF CERTAIN
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 CERTAIN RELATIONSHIPS AND TRANSACTIONS WITH RELATED PERSONS 20 DIRECTOR COMPENSATION 21 EXECUTIVE OFFICERS OF THE COMPANY 23 NAMED EXECUTIVE OFFICER COMPENSATION 24 AUDIT COMMITTEE REPORT 35 DELIVERY OF PROXY MATERIALS 36 ADDITIONAL INFORMATION 37 ANNEX A 39 i AKARI THERAPEUTICS, PLC (Registered in England & Wales, No. 05252842) Registered office: Highdown House, Yeoman Way, Worthing, West Sussex BN99 3HH PROXY STATEMENT FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 INFORMATION CONCERNING PROXY SOLICITATION AND VOTING We have sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the “Board of Directors” or “Board”) of Akari Therapeutics, Plc (referred to herein as the “Company”, “we”, “us” or “our”) is soliciting your proxy to vote at our annual general meeting of shareholders (referred to herein as the “Meeting” or the “AGM”) to be held at 2:00 p.m. London time (9:00 a.m. Eastern Time), on June 27, 2024, at 75/76 Wimpole Street, London, W1G 9RT. This Proxy Statement summarizes information about the resolutions to be considered at the Meeting and other information you may find useful in determining how to vote. The form of proxy is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews. All costs of solicitation of proxies will be covered by us. We are mailing the Notice of AGM, this Proxy Statement, the proxy card and our Annual Report on Form 10-K for the financial year ended December 31, 2023 (the “Annual Report on Form 10-K”) to our ordinary